Topoisomerase I inhibitors and other new cytotoxic drugs.
Verweij
J
J
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D045563:Indolequinones; D007211:Indoles / Q000627:therapeutic use; D000077146:Irinotecan; D007783:Lactones / Q000627:therapeutic use; D018942:Macrolides; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D059004:Topoisomerase I Inhibitors; D000093542:Gemcitabine
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001388:Aziridines; D045563:Indolequinones; D007211:Indoles; D007783:Lactones; D018942:Macrolides; D009944:Organoplatinum Compounds; D011799:Quinazolines; D013876:Thiophenes; D059004:Topoisomerase I Inhibitors; D003841:Deoxycytidine; C066998:methoxy-morpholinyl-doxorubicin; D000077146:Irinotecan; D004317:Doxorubicin; C081294:satraplatin; C041443:rhizoxin; D013940:Thymidylate Synthase; C068874:raltitrexed; C060817:apaziquone; D002166:Camptothecin; D000093542:Gemcitabine